Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has completed a milestone year marked by significant improvements in ...

The late-stage chronic kidney disease (CKD) market is experiencing significant growth, driven by rising global prevalence of diabetes, hypertension, and aging populations. Advanced treatments like ...

The Dialysafe trial aimed to reduce episodes of intradialytic hypotension during hemodialysis sessions at the clinic level.

Why funding lags: Kidney disease research receives far less funding than other chronic conditions, limiting innovation and keeping dialysis as the default treatment. Who’s driving change: Companies ...

The number of foreign-owned business rose 4% last year in California despite the Trump administration's trade wars, with ...

UB faculty member Calvin Meaney highlights the benefits of relying on pharmacists, especially with the shortage of ...

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

Fresenius Medical Care FME-3.00%decrease; red down pointing triangle shares fell after the German dialysis specialist forecast flattish revenue and adjusted earnings in the year ahead amid regulatory ...

Detailed price information for Fresenius Medical Care Ag ADR (FMS-N) from The Globe and Mail including charting and trades.

The proposed aflibercept biosimilar is intended to treat ophthalmic disorders. This FDA submission follows the licensing agreement under which Fresenius Kabi will exclusively commercialize the ...

Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation ...